Childhood cancer survivors face long-term health risks from treatment including cardiac, pulmonary, and endocrine complications.

Radiation therapy increases risk of secondary malignancies, with latency periods often exceeding 10-20 years post-treatment.

Anthracycline chemotherapy causes dose-dependent cardiotoxicity requiring lifelong cardiac surveillance in survivors.

Neurocognitive deficits from CNS-directed therapy may not manifest until years after treatment completion.

Survivorship care plans should address fertility preservation, growth monitoring, and psychosocial support needs.

Late Effects of Treatment for Childhood Cancer PDQ® | GlobalCastMD Clinical Guidelines

Guideline document

This guideline is provided for in-page reading only. Please contact the publishing organization for downloadable copies.

Topic overview

NCI's evidence-based clinical reference for healthcare professionals managing long-term complications in childhood cancer survivors. Covers organ-specific toxicities, secondary malignancies, and surveillance strategies following chemotherapy, radiation, and surgical interventions.

Key Takeaways

Childhood cancer survivors face long-term health risks from treatment including cardiac, pulmonary, and endocrine complications.
Radiation therapy increases risk of secondary malignancies, with latency periods often exceeding 10-20 years post-treatment.
Anthracycline chemotherapy causes dose-dependent cardiotoxicity requiring lifelong cardiac surveillance in survivors.
Neurocognitive deficits from CNS-directed therapy may not manifest until years after treatment completion.
Survivorship care plans should address fertility preservation, growth monitoring, and psychosocial support needs.

Keywords

Hashtags

#PediatricOncology #CancerSurvivorship #LateEffects #ChildhoodCancer

Full guideline text

Full text not available for this guideline

How to cite: GlobalCastMD. Late Effects of Treatment for Childhood Cancer PDQ®. GlobalCastMD Medical Library. https://library.globalcastmd.com/guideline/2369